Patient Selection and Assessment for the CardioMEMS HF System | Abbott
CARDIOVASCULAR
hamburger
CARDIOMEMS HF SYSTEM

Patient Selection & Assessment

Selecting the Right Patient

The CardioMEMS™ HF System is indicated for patients with:¹

  • NYHA Class II or Class III heart failure; and
  • One heart failure hospitalization in the past 12 months; and/or
  • Have elevated natriuretic peptides

The CardioMEMS HF System is contraindicated for patients with:

  • An inability to take dual antiplatelet or anticoagulants for one-month post implant

Patients who most commonly receive the CardioMEMS HF System are those on GDMT and those who exhibit any of the following:²

  • Fluid volumes that are hard to know or manage
  • Challenging physical assessment
  • Is a patient with HFpEF or HFrEF
  • Compliant with heart failure medical care
  • Would benefit from remote monitoring if they live far from a clinic

Note: The CHAMPION trial specifically excluded patients with American College of Cardiology/ American Heart Association stage D heart failure who needed advanced therapies (i.e., left ventricular assist device, transplant or inotropic support). Even if inotropic support improved heart failure symptoms, a patient would still be defined as stage D, with refractory heart failure.²

Stages of Heart Failure

Patient Selection Resources

Patient Candidate Considerations Tool

This document provides information to select heart failure patients who would benefit most from the CardioMEMS HF System, along with BNP thresholds.

CardioMEMS HF System Patient Approach with Philip B. Adamson, MD, MSC, FACC (06:01)

In this video, Philip B. Adamson, M.D., MSc, FACC, reviews essential tips for approaching patients about their symptoms and engaging in conversation about the CardioMEMS HF System.

CardioMEMS HF System Patient Approach with Jamie Pelzel, MD (07:43)

In this video, Jamie Pelzel, MD, reviews essential tips to approaching patients about their symptoms and engaging in conversation about the CardioMEMS HF System.

CardioMEMS HF System Patient Approach with Stephanie Preister, CNP (05:46)

In this video, Stephanie Preister, CNP, leads a discussion with patients about the CardioMEMS HF System and patient compliance.

References

  1. Lindenfeld J, Zile MR, Desai AS, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomized controlled trial. The Lancet. 2021;398:991-1001.
  2. Abraham, W. T., Adamson, P. B., Bourge, R. C., Aaron, M., Costanzo, M. R., Stevenson, L. W., …Yadav, J. S., for the CHAMPION Trial Study Group. (2011). Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial. The Lancet, 377(9766), 658-666. https://dx.doi.org/10.1016/S0140-6736(11)60101-3
INDICATIONS, SAFETY & WARNINGS

MAT-2006770 v5.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.